Never miss an update from Alexion Pharmaceuticals. Did you know that during reporting season, the announcements from NASDAQ:ALXN often move the market?
|52w High/Low:||$94.59 - 141.86|
|Volume/Average:||1.7M - 2M|
Listed in 1996Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products... More
The pre-commercial company is looking to take on a $23 billion industry leader. Promising late-stage clinical results suggest it may have a shot.3 Top Biotech Stocks to Buy Right Now
Here are three biotech companies with solid, revenue-driving products to add to portfolios while the price is right.6 Industries That Are Historically Cheap, Even With the Stock Market at an All-Time High
Many of these industries have recently been valued at their lowest forward P/E in at least 22 years.Here's Why Apellis Pharmaceuticals Stock Jumped as Much as 40.7% Today
The company's lead drug candidate bested a competitor's therapy on a key endpoint in a phase 3 trial.Apellis' Lead Drug Tops Alexion's Blockbuster Soliris in a Pivotal Late-Stage Study
Pegcetacoplan is the first drug to beat Soliris in improving hemoglobin levels in PNH patients.Here's Why Dicerna Pharmaceuticals Is Falling Today
What goes up must come down. But today's tumble means relatively little for investors with a long-term mindset.Better Buy: Vertex Pharmaceuticals vs. Alexion Pharmaceuticals
Both of these drugmakers have solid portfolios and treatment pipelines, but savvy investors will find good reason to favor one over the other.3 Healthcare Stocks With Heightened Expectations
These health-related businesses managed to surprise themselves.